WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive…
CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human,…
Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million…
Conference Call and Webcast Today at 8:30 a.m. ETReceived alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase…
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical…
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or…
Company to host investor call and webcast on Monday, April 1st, at 8:30am EDTPITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) --…
Two Merck leaders share how their company is working to help protect communities from vaccine-preventable illnessesNORTHAMPTON, MA / ACCESSWIRE /…
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The…
